pittplusme.org/study/2022
ELATIVE Study
STUDY BASICS
Do you have Primary Biliary Cholangitis (PBC)? You may be able to participate in a study to find out how safe and effective an investigational drug called elafibranor is for patients with PBC. The main part of the study lasts up to 2 years, but total participation can last up to 6 years. Compensation and reimbursement are provided.
IRB: 20200353
- A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients with Primary Biliary Cholangitis with Inadequate Response or Intolerance to Ursodeoxycholic Acid
AGE:
18-75
DURATION:
Up to 6 years
VISITS:
Up to 21
LOCATION:
Kaufmann Building – Oakland
COMPENSATION:
$100 per completed visit
SHARE STUDY
MEET THE RESEARCHER
Mordechai Rabinovitz
Mordechai Rabinovitz, MD, is a Professor of Medicine in the Division of Gastroenterology, Hepatology, and Nutrition at the University of Pittsburgh. A graduate of Tel-Aviv University in Israel, Dr. Rabinovitz’s research interests include assessment and treatment of chronic viral hepatitis as well as developing new therapies for non-alcoholic fatty liver disease.